TY - JOUR
T1 - Treatment and surveillance of advanced, metastatic iodine-resistant differentiated thyroid cancer
AU - Ibrahim, Eiman Y.
AU - Busaidy, Naifa L.
N1 - Publisher Copyright:
© 2017 Wolters Kluwer Health, Inc.
PY - 2017/3/1
Y1 - 2017/3/1
N2 - Purpose of review This review will focus on the management and treatment of metastatic thyroid cancer that is radioactive iodine refractory and review the new drugs and their mechanism of actions as well as their adverse events. Recent findings Until recently, there were no efficacious therapeutic modalities for these patients. With advancement in knowledge and research of the molecular aberrations and oncogenic mutations in thyroid cancer as well as further understanding the role of angiogenesis in tumor growth molecular pathogenesis, novel targeted therapies are available for these patients. Some of these drugs have successfully prolonged progression free survival and are now Food and Drug Administration approved. Additional agents are approved for the treatment of other types of cancers and are currently under investigation for differentiated thyroid cancer treatment. Summary Differentiated thyroid cancer (papillary and follicular) is the most common endocrine malignancy. It is generally known to have an excellent prognosis and patients are usually cured with the conventional primary treatments including surgery, radioactive iodine, and thyroid stimulating hormone suppression. A minor proportion of patients do not fully recover mainly because they develop radioactive iodine-resistant disease. These patients have few treatment options, which we aimed to describe here.
AB - Purpose of review This review will focus on the management and treatment of metastatic thyroid cancer that is radioactive iodine refractory and review the new drugs and their mechanism of actions as well as their adverse events. Recent findings Until recently, there were no efficacious therapeutic modalities for these patients. With advancement in knowledge and research of the molecular aberrations and oncogenic mutations in thyroid cancer as well as further understanding the role of angiogenesis in tumor growth molecular pathogenesis, novel targeted therapies are available for these patients. Some of these drugs have successfully prolonged progression free survival and are now Food and Drug Administration approved. Additional agents are approved for the treatment of other types of cancers and are currently under investigation for differentiated thyroid cancer treatment. Summary Differentiated thyroid cancer (papillary and follicular) is the most common endocrine malignancy. It is generally known to have an excellent prognosis and patients are usually cured with the conventional primary treatments including surgery, radioactive iodine, and thyroid stimulating hormone suppression. A minor proportion of patients do not fully recover mainly because they develop radioactive iodine-resistant disease. These patients have few treatment options, which we aimed to describe here.
KW - differentiated thyroid cancer
KW - mitogen-activated protein kinase inhibitors
KW - radioactive iodine refractory
KW - thyroid cancer
KW - tyrosine kinase inhibitors
UR - http://www.scopus.com/inward/record.url?scp=85011306612&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85011306612&partnerID=8YFLogxK
U2 - 10.1097/CCO.0000000000000349
DO - 10.1097/CCO.0000000000000349
M3 - Review article
C2 - 28141684
AN - SCOPUS:85011306612
SN - 1040-8746
VL - 29
SP - 151
EP - 158
JO - Current opinion in oncology
JF - Current opinion in oncology
IS - 2
ER -